RE:RE:Live depiction of Mesenchymal MSCI don`t understand your statement. How are you defining timely?
A lot of people on this forum are stating timely as testign results are aligned with mainstream attention to stem cell treatment.
If this is not a COVID play, then timely is not really a problem. As long as the company announces profit (no deficit) quarterly, this company is doing just fine - which it is on mesenchymal stem cells (MSC).
And yes, they are following Pluristem and Mesoblast because they are US based stocks whereas LBL is a TSX based stock.It relies on "additional" supporting evidence from them and around the world to help its company build a stronger case that stem cell is actually working. WHICH it is hitting mainstream every so often. It is just a matter of time that more attention will be had on
Amniboost is a multi-play (COVID-19 included). Their news release speaks it out. I'm sure you've seen it since you're huge on references made to articles.
They will likely hit phase II very soon - based on other companies that have had success with MSC. This will gradually climb in the coming days.
Boobah wrote: The research isn't the question. We know from all the other studies this is working. The question is can lattice deliver in a timely manor. They pretty much have a paved road following behind pluristem and mesoblast. I don't think aminoboost is a "covid" play, but if they can advance in a phase 2-3 during this, our stock will benefit 10 fold.